Format

Send to

Choose Destination
Clin Res Hepatol Gastroenterol. 2014 Oct;38(5):570-6. doi: 10.1016/j.clinre.2014.07.004. Epub 2014 Aug 15.

Aspirin may reduce liver fibrosis progression: Evidence from a multicenter retrospective study of recurrent hepatitis C after liver transplantation.

Author information

1
Service d'hépatologie, hôpital Saint-Antoine, 184, rue du faubourg Saint-Antoine, 75012 Paris, France. Electronic address: armelle.poujol-robert@sat.aphp.fr.
2
Service de santé publique, hôpital Saint-Antoine, AP-HP, Paris, France.
3
Centre de transplantation hépatique, hôpital Saint-Antoine, AP-HP, Paris, France.
4
Service d'hépatologie et réanimation hépatodigestive, hôpital Beaujon, AP-HP, Clichy, France.
5
Service d'hépato-gastroentérologie, hôpital Henri-Mondor, AP-HP, Créteil, France.
6
Service d'anatomie et de cytologie pathologiques, hôpital Saint-Antoine, AP-HP, Paris, France.
7
Département d'anatomie pathologique, hôpital Beaujon, AP-HP, Clichy, France.
8
Secteur de virologie, service de microbiologie, hôpital Beaujon, AP-HP, Clichy, France.
9
Service d'hépatologie, hôpital Saint-Antoine, 184, rue du faubourg Saint-Antoine, 75012 Paris, France; UMR S938, faculté de médecine Pierre-et-Marie-Curie, site Saint-Antoine, Paris, France; Université Pierre-et-Marie-Curie (UPMC) Paris 6, Paris, France.
10
Service d'hépatologie, hôpital Saint-Antoine, 184, rue du faubourg Saint-Antoine, 75012 Paris, France.

Abstract

BACKGROUND AND AIMS:

There is evidence for an association between thrombosis in the hepatic microcirculation and liver fibrosis. The aim of this study was to evaluate the role of daily low-dose aspirin (75 or 100mg, given for prevention of hepatic artery thrombosis) in fibrosis progression to ≥ F2 fibrosis score in liver-transplant recipients with recurrent hepatitis C virus (HCV).

METHODS:

All HCV-positive patients who had undergone liver transplantation (LT) between 2000 and 2010 were included. Exclusion criteria were negative HCV RNA, previous LT or death within a year of LT. Liver fibrosis was assessed by histological evaluation. Data were censored at the date of the last histological evaluation before starting anti HCV therapy. Progression to fibrosis F ≥ 2 was analyzed with a multistate model with time-dependent covariables.

RESULTS:

One hundred and eighty-eight patients were included. In univariate analysis, older recipient and donor age, male donor gender, activity score ≥ A2 after LT, number of steroid boluses and aspirin intake (HR: 0.75 [0.57-0.97]; P=0.03) influenced the risk of progression to fibrosis ≥ F2. In multivariate analysis, adjusted on site, older donor age, male donor gender, activity score ≥ A2 and number of steroids boluses, remained independent predictors of fibrosis progression, while younger recipient age and aspirin intake (HR: 0.65 [0.47-0.91]; P=0.01) were associated with a slower fibrosis progression.

CONCLUSION:

Low-dose aspirin treatment might be associated with a lower risk of liver fibrosis progression in patients with HCV recurrence after LT.

PMID:
25130796
DOI:
10.1016/j.clinre.2014.07.004
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center